Earnings call transcript: Camtek tops Q3 2026 estimates but shares fall

Camtek reported record Q3 2026 revenue of $161.3 million, up 28% year over year, and non-GAAP diluted EPS of $0.99; management’s initial 2027 revenue outlook is more than $800 million, with a roughly $1.2 billion target within about three years. Gross margin was 51.1%, down from 51.4% in Q2, as component costs and supply constraints weighed, though management expects gradual improvement from Q1 2027. Shares fell 8.66% to $32,710 despite the reported beat, reflecting investor concern about margins and future upside.

Analysis

The first risk is data integrity: the article’s headline figures ($510.14M revenue, $3.13 EPS) conflict materially with the earnings-call figures ($161.3M revenue, $0.99 diluted EPS). Verify the company filing and correct reporting period before relying on the stated beat or building estimates; the mismatch may itself explain why the reported market reaction is hard to interpret.

For CAMT, the key debate is whether a strong shipment ramp can convert into durable gross-margin expansion. Operating leverage is visible, but gross margin remained essentially flat sequentially as component costs rose. Management’s 2027 improvement case depends on price increases, mix, supply normalization and software monetization—offsets that are not yet independently demonstrated. Delivery-slot reservations extending into 2027 offer visibility, but are not equivalent to non-cancellable revenue, and may be constrained by component availability.

Over 1–3 months, track gross margin, order conversion/cancellations and delivery performance. Over 6–18 months, the upside case requires software to generate meaningful revenue and service growth to scale without diluting margins; both are execution risks, not yet established earnings streams. Asia exposure and OSAT concentration amplify sensitivity to regional capex or trade restrictions. KLA (KLAC) could benefit from broader adoption of advanced-packaging inspection, while also raising competitive pressure for CAMT; the timing and product overlap remain uncertain.

Contrarian point: a sharp post-results decline can overstate near-term deterioration if backlog converts and pricing offsets input costs. Conversely, booking visibility may be receiving too much credit if customers reserve capacity ahead of actual needs. No valuation-based conclusion is warranted without verified figures and current estimates.

Key Decisions for Investors

• Do not trade the reported beat or its size until CAMT’s filing confirms the correct revenue, EPS, period and consensus comparison. Treat the discrepancy as a data-quality alert.
• Keep CAMT on a catalyst watch rather than adding on the selloff. Reassess after the next report: evidence of sequential gross-margin improvement, on-time deliveries and firm order conversion would support a long; margin deterioration or cancellations would invalidate that case.
• For a relative-value watch, consider CAMT versus KLAC only after confirming valuation and product-level exposure. The thesis is that KLAC may be less exposed to CAMT-specific execution while still participating in advanced-packaging inspection; broader market overlap is not assured.
• Monitor Asia-related export controls and customer-capex signals, component availability and CAMT pricing realization. These are the clearest near-term falsifiers of the demand-and-margin recovery thesis.